Biocytogen Announces U.S. Food and Drug Administration IND Clearance for Partner NEOK Bio’s NEOK002 in Solid Tumor Indications
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. has announced a significant regulatory milestone achieved by its partner, NEOK Bio, Inc., highlighting continued progress in the development of next-generation antibody-based cancer therapies. The partner company recently received clearance from the U.S. Food and Drug Administration (FDA) for an investigational new drug (IND) application supporting NEOK002, an innovative antibody-drug conjugate (ADC) designed to target solid tumors through a dual-antigen approach.
This regulatory clearance marks a pivotal step in the advancement of NEOK002, enabling NEOK Bio to proceed into clinical development. The company has outlined plans to initiate a Phase 1 clinical trial in the second quarter of 2026. This early-stage study will primarily focus on evaluating the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of the investigational therapy in patients with advanced solid tumors. Initial clinical data from this trial are anticipated in 2027, which will provide important insights into the therapeutic potential of the candidate.
NEOK002 represents a promising new approach within the rapidly evolving field of antibody-drug conjugates, a class of targeted cancer therapies that combine the specificity of monoclonal antibodies with the cytotoxic potency of chemotherapy agents. What distinguishes NEOK002 is its bispecific design, which enables it to simultaneously target two tumor-associated antigens—EGFR (epidermal growth factor receptor) and MUC1 (mucin 1). Both targets are widely expressed across a range of solid tumors and are associated with tumor growth, survival, and resistance mechanisms.
By engaging both EGFR and MUC1, NEOK002 is designed to enhance tumor selectivity and potentially overcome limitations associated with monospecific ADCs, which target only a single antigen. Traditional ADCs directed at either EGFR or MUC1 alone have shown clinical activity but may be limited by issues such as heterogeneous antigen expression, off-target toxicity, or resistance development. The dual-targeting strategy employed by NEOK002 aims to improve tumor cell binding and internalization, thereby increasing the delivery of cytotoxic payloads directly to cancer cells while minimizing effects on healthy tissues.
The origins of NEOK002 can be traced back to Biocytogen’s proprietary antibody discovery platform. The underlying bispecific antibody used in the ADC was initially developed by Biocytogen and subsequently licensed to NEOK Bio in 2024. This collaboration reflects Biocytogen’s broader strategy of leveraging its technology platforms to generate high-quality therapeutic candidates and partnering with other biotechnology companies to advance them through clinical development.
Central to this effort is Biocytogen’s RenLite® platform, a proprietary system designed to generate fully human antibodies with enhanced developability characteristics. The platform incorporates a common light chain design, which simplifies the engineering and manufacturing of bispecific antibodies. This approach not only improves efficiency during drug development but also helps ensure favorable biophysical properties, such as stability and reduced immunogenicity, which are critical for clinical success.
Dr. Yuelei Shen, President and Chief Executive Officer of Biocytogen, expressed optimism about the milestone, emphasizing its importance as validation of the company’s technology and scientific capabilities. He noted that the advancement of NEOK002 into clinical trials underscores the quality and therapeutic potential of the antibodies generated using the RenLite® platform. According to Dr. Shen, this achievement reinforces confidence in the platform’s ability to produce innovative biologics that can address unmet medical needs in oncology.
The IND clearance also highlights the growing importance of strategic collaborations in the biotechnology sector. By partnering with NEOK Bio, Biocytogen has been able to extend the reach of its discovery efforts and accelerate the translation of its research into clinical applications. For NEOK Bio, access to Biocytogen’s advanced antibody technologies provides a strong foundation for developing differentiated therapies in a highly competitive oncology landscape.
From a broader perspective, the development of NEOK002 reflects ongoing innovation in the design of ADCs and bispecific antibodies. These modalities are increasingly being combined to create more precise and effective cancer treatments. As researchers continue to explore new ways to enhance targeting specificity and therapeutic index, dual-targeting ADCs like NEOK002 may represent a next wave of innovation with the potential to improve outcomes for patients with difficult-to-treat solid tumors.
As the program moves into its first-in-human study, the upcoming Phase 1 trial will be closely watched by clinicians, researchers, and industry stakeholders. The results will not only inform the future development of NEOK002 but may also provide valuable insights into the broader applicability of bispecific ADC technologies.
In summary, the FDA’s clearance of the IND application for NEOK002 marks a critical transition from preclinical research to clinical evaluation. It underscores the collaborative success between Biocytogen and NEOK Bio, validates the underlying antibody technology, and sets the stage for further advancements in targeted cancer therapy. With clinical trials on the horizon, NEOK002 has the potential to contribute meaningfully to the evolving landscape of oncology therapeutics, particularly in the treatment of solid tumors where new and more effective options remain urgently needed.
About Biocytogen
Biocytogen (SSE: 688796; HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen has established a dual-engine platform combining a fully human antibody library with an extensive target-humanized mouse model portfolio, enabling a systematic approach to accelerating global drug discovery and development.
Biocytogen has independently developed its proprietary RenMice® (RenMab®/RenLite®/RenNano®/RenTCR™/RenTCR mimic™) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, hu-VHH discovery, and TCR mimic antibody discovery, and has established a sub-brand, RenSuper™ Biologics, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration.
“As of December 31, 2025, more than 350 agreements for therapeutic antibodies and clinical assets—spanning co-development, out-licensing, and transfers—have been established globally, including landmark partnerships with leading multinational pharmaceutical companies (MNCs).”Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company’s sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen, Jiangsu, Shanghai), the USA (Boston, San Francisco, San Diego), and Germany (Heidelberg).
Source Link:https://www.businesswire.com/
